Concordia Healthcare (NASDAQ: CXRX) reported Q3 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $94.9 million versus the consensus estimate of $93.92 million. Concordia Healthcare reaffirmed FY2016 guidance.

"The third quarter of 2015 has been one of the most significant and important periods in Concordia's history. We completed the acquisition of AMCo, which has transformed Concordia into a global organization with more than 200 well-established legacy products sold in over 100 countries," said Mark Thompson, Chairman and Chief Executive Officer of Concordia.

For earnings history and earnings-related data on Concordia Healthcare (CXRX) click here.